Skip to main content
Premium Trial:

Request an Annual Quote

Pharsight to Support FDA s Critical Path Initiative

NEW YORK, June 7 (GenomeWeb News) - Pharsight has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration's Center for Drug Evaluation and Research, the firms said today.


Under the terms of the CRADA, Pharsight will use its software to analyze, visualize, store, report, and review pharmacokinetic and pharmacodynamic data.


Pharsight will also provide CDER with its suite of software tools, including Pharsight Knowledgebase Server, the PKS Validation Suite, its WinNonlin Validation Suite, its Drug Model Explorer, and its Pharsight Trial Simulator. CDER will use the Pharsight tools to review clinical trial data, especially for clinical pharmacology and clinical safety reviews, and will provide feedback to Pharsight, the company said.


According to Robert Powell, head of pharmacometrics in FDA's Office of Clinical Pharmacology, the collaboration directly supports the FDA's Critical Path Initiative, which advocates increased use of drug-disease modeling and simulation to improve the efficiency of the drug product development process.


Financial details were not discussed.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.